Targeted (Intra)arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab Paclitaxel following Induction with Sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC)
Sponsor: |
RenovoRx |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT5973 |
U.S. Govt. ID: |
NCT03257033 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
One of the major reasons given for the failure of pancreatic cancer chemotherapy to work effectively in preventing the growth of the cancer is because when given through a vein that goes throughout the body, the chemotherapy does not properly reach the tumor to produce its effect. The purpose of this research study is to find out whether using a newer method of targeted local delivery of the chemotherapy directly into an artery close to the pancreas tumor after treatment with standard chemotherapy that is delivered by vein is more effective at preventing the tumor from growing as compared with just receiving standard chemotherapy into a vein that goes throughout the body. This study will compare how IA and IV medication affects the time that patients survive and their quality of life.
Investigator
Susan Bates, MD
Are you age 18 or older? |
Yes |
No |
Have you been diagnosed with pancreatic cancer? |
Yes |
No |
Do you have HIV or hepatitis? |
Yes |
No |